Dr. rer.-nat. Anne Wolf

Zentrum für Augenheilkunde
Experimentelle Immunologie des Auges
Uniklinikum Köln
Joseph-Stelzmann-Str. 9
50931 Köln
+49 221 478 84592
anne.wolf@uk-koeln.de

Projekte:

Projektleiterin

C06

Wissenschaftliche Karriere

Seit 2015 Assoziierte Doktorandin im Projekt 6 „Rolle des Komplementsystems und der Mikroglia bei der altersbedingten Makuladegeneration“ der DFG-Forschergruppe FOR 2240 „Angiogenese, Lymphangiogenese und zelluläre Immunität bei entzündlichen Erkrankungen des Auges“, Zentrum für Augenheilkunde, Experimentelle Immunologie des Auges Universität zu Köln

2020 Promotion (“summa cum laude”) in Biologie, Universität zu Köln, Prof. Dr. Thomas Langmann

Since 2020 Laborleiterin, Experimentelle Immunologie des Auges, Universität zu Köln

Since 2023 Co-PI ZMMK-B07 „Retinal microglia and their immunological effects in AAV-based ocular gene therapy“

2024 PostDoc im Maisonneuve-Rosemont Research Center an der Université de Montréal, Canada. Prof. Przemyslaw (Mike) Sapieha.

Since 2024 PI im SFB 1607 „Towards immunomodulatory and anti(lymph)angiogenic therapies for age-related blinding eye diseases“.

Since 2024 PI in CAP (Career Advancement Program) Group 34 am ZMMK (Zentrum für Molekulare Medizin Köln)

Preise und Ehrungen

2013 Jahrgangsbeste, Bachelor of Science in Biologie, Universität zu Köln

2015-2018 PhD Fellowship VELUX Foundation

2018 Pro Retina Travel Award

2019 IPaK Travel Award

2019 Retina Suisse Award

2020 Deutscher Förderpreis für Augenheilkunde, Bayer (50,000 €)

Since 2022 Mitherausgeberin, Cellular Neuropathology (Frontiers in Cellular Neuroscience)

Since 2024 Gender Board Mitglied SFB 1607

2024 Förderpreis Freifrau von Nauendorf-Stiftung (10,000 €)

Selected publications

  1. Hector, M., Behnke, V., Dabrowska-Schlepp, P., Busch, A., Schaaf, A. Langmann, T., Wolf, A. (2025) Moss‑derived human complement factor H modulates retinal immune response and attenuates retinal degeneration. J Neuroinflammation, doi: 10.1186/s12974-025-03418-2. Accepted and in press. Impact factor: 9.3. Corresponding author.
  2. Behnke, V., Wolf, A., Hector, M., Langmann, T. (2025) C3aR1-Deletion Delays Retinal Degeneration in a White-Light Damage Mouse Model. Invest Ophth Vis Sci 66, doi: 10.1167/iovs.66.1.15. Impact factor: 5.0
  3. Ciurus, S., Elewa, MAF., Palmer, MA,, Wolf, A., Hector, M., Fuhrmann, DC., Thomas, D., Gurke, R., Schwalm, MP., Berger, L., Zech, TJ., Burgers, LD., Marschalek, R., Geisslinger, G., Knapp, S., Langmann, T., Bracher. F., Weigert, A., Fürst, R. (2025) Inhibition of DYRK1B BY C81 impedes inflammatory processes in leukocytes by reducing STAT3 activity. Cell Mol Life Sci 82: 85, doi: 10.1007/s00018-025-05579-y. Impact factor: 6.2
  4. Zech TJ, Wolf A, Hector M, Bischoff-Kont I, Krishnathas GM, Kuntschar S, Schmid T, Bracher F, Langmann T, Fürst R (2024) 2-Desaza-annomontine (C81) impedes angiogenesis through reduced VEGFR2 expression derived from inhibition of CDC2-like kinases. Angiogenesis 27: 245-272, doi: 10.1007/s10456-024-09906-y. Impact factor: 9.2
  5. Hector, M., Langmann, T., Wolf, A. (2024) Translocator protein (18 kDa) (Tspo) in the retina and implications for ocular diseases. Prog Retin Eye Res 100: 101249, doi:10.1016/j.preteyeres.2024.101249. Impact factor: 18.7. Corresponding author.
  6. Diaz-Lezama N, Wolf A, Koch S, Pfaller AM, Biber J, Guillonneau X, Langmann T, Grosche A (2021) PDGF Receptor Alpha Signaling Is Key for Muller Cell Homeostasis Functions. Int J Mol Sci 22, doi: 10.3390/ijms22031174. Impact factor: 5.6
  7. Tabel M, Wolf A, Szczepan M, Xu H, Jagle H, Moehle C, Chen M, Langmann T (2022) Genetic targeting or pharmacological inhibition of galectin-3 dampens microglia reactivity and delays retinal degeneration. J Neuroinflammation 19: 229, doi: 10.1186/s12974-022-02589-6. Impact factor: 9.3
  8. Khan, A. S., Wolf, A. & Langmann, T. (2021). The AhR ligand 2, 2′-aminophenyl indole (2AI) regulates microglia homeostasis and reduces pro-inflammatory signaling. Biochem Biophys Res Commun, 579, 15-21, doi:10.1016/j.bbrc.2021.09.054. Impact factor: 2.5
  9. Wolf, A., Herb, M., Schramm, M., & Langmann, T. (2020). The TSPO-NOX1 axis controls phagocyte-triggered pathological angiogenesis in the eye. Nat Commun, 11(1), 2709. doi:10.1038/ s41467-020-16400-8. Impact factor: 14.91
  10. Kinuthia, U. M., Wolf, A., & Langmann, T. (2020). Microglia and Inflammatory Responses in Diabetic Retinopathy. Frontiers in Immunology, 11(2888). doi:10.3389/fimmu.2020.564077. Impact factor: 7.56
  11. Behnke, V., Wolf, A., Langmann, T. (2020). The role of lymphocytes and phagocytes in age- related macular degeneration (AMD). Cell Mol Life Sci, 77(5), 781-788. doi:10.1007/ s00018-019-03419-4. Impact factor: 9.26
  12. Wolf, A., & Langmann, T. (2019). Anti-VEGF-A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study. EMBO Mol Med, 11(5). doi:10.15252/ emmm.201910362. Impact factor: 12.13
  13. Herb, M., Gluschko, A., Wiegmann, K., Farid, A., Wolf, A., Utermohlen, O., Krug, O., Krönke, M., Schramm, M. (2019). Mitochondrial reactive oxygen species enable proinflammatory signaling through disulfide linkage of NEMO. Sci Signal, 12(568). doi:10.1126/scisignal.aar5926. Impact factor: 8.19
  14. Balser, C.* and Wolf, A.*, Herb, M., & Langmann, T. (2019). Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina. J Neuroinflammation, 16(1), 26. doi:10.1186/s12974-019-1419-2. Impact factor: 8.32

Projekt­bezogene Publikationen

X